導師資訊

5002 N22 ICMS University of Macau

University of Macau

UMAC-SKL of Quality Research in Chinese Medicine

https://sklqrcm.um.edu.mo/xiu-ping-chen/

隱丹參酮協同NQO1生物激活藥物抗腫瘤分子機制與新藥研發

Mechanistic and translational study on the synergistic activity of cryptotanshinone combined with NQO1 bioactivatable drugs in cancer

1007 药学

1008 中药学

Obtain PhD degree on or after 2023

Pharmacology, biology, and medicine background

Preclinical study of natural products regulating programmed cell death We mainly focuses on the preclinical development of naturals products that regulate programmed cell death (PCD). By using integrated platforms, we have identified naturals products with distinct mechanisms of action to induced PCD. We demonstrate that 2-methoxy-6-acetyl-7-methyljuglone (MAM), a type of quinone, induce cell-type dependent PCD dependent on ROS, caspase, RIPK1, or NQO1. We report for the first time that the form of PCD induced by MAM is distinct to any other types of PCD reported, and highly dependent on NQO1-mediated ROS production. We term this novel type of PCD as noptosis. We are still working on the underlying mechanisms and signaling that lead to noptosis. The therapetutic potential of noptosis is also being explored. Development of epithelial-mesenchymal transition inhibitors Epithelial-mesenchymal transition (EMT) is of pivotal importance in controlling tumor metastasis and organ fibrosis. By u

10

8

6

Mechanistic and translational study on the synergistic activity of cryptotanshinone combined with NQO1 bioactivatable drugs in cancer, FDCT, 0070/2022/A2, 2,234,000.00, 3 years